Cardiac and systemic inflammation in cardiogenic shock

Purpose of review The understanding of cardiogenic shock (CS) has significantly evolved over the past decades. Initially regarded as a purely mechanistic syndrome, CS is now recognized as a multifaceted condition that incorporates a complex interplay of hemodynamic compromise and a cascading inflammatory response. This review aims to describing cardiac and systemic inflammation involvement in cardiogenic shock Recent findings Defining subphenotypes among CS patients is mandatory as it is no longer considered as a homogeneous entity. Accordingly, including inflammatory biomarkers in a risk-stratification approach and identifying populations who will predictably respond to tailored therapies is a major concern. Summary In this review, we propose a narrative review on cardiac and systemic inflammation occurring in CS, current research on inflammatory biomarkers and their implications in risk-stratification, and upcoming trials on therapies targeting inflammation.